Topical safety is one of the most critical factors when developing advanced skin therapies, especially for use on compromised, chronic, or surgically exposed tissue. A rigorous dermal irritation test is required to validate that a product can be applied without triggering inflammation, allergic response, or chemical burns.
In 2019, UNIPREC’s Preclinical Research Unit at UNAM conducted a standardized dermal irritation test on Ion Gel ZCM-25®, a Class II medical gel featuring the redox-active compound ION-ZCM1. The study simulated maximum clinical exposure, applying five times the recommended human dose. The results: Primary Irritation Index of 0. No erythema, edema, or adverse reactions.
The dermal irritation test followed global preclinical safety standards for topical therapeutics. The procedure included:
The entire study was overseen by veterinary staff and conformed to ethical treatment guidelines.
The results of the dermal irritation test were definitive:
These outcomes show that Ion Gel ZCM-25® poses no irritation risk, even at elevated concentrations, and is suitable for use on broken, inflamed, or healing skin.
The dermal irritation test is more than a checkbox for regulatory approval. It is crucial for ensuring patient comfort, reducing the risk of allergic dermatitis, and confirming suitability for:
Because Ion Gel ZCM-25® is intended for repeated use, its non-irritant status provides strong reassurance for both clinicians and patients.
The excellent outcome of the dermal irritation test is directly linked to the unique formulation of Ion Gel ZCM-25®, which features:
Ion Biotechnology Aqueous Ligands (IBAL) enable ion delivery without traditional excipients like alcohols, surfactants, or preservatives. This reduces sensitization risk.
This skin-conditioning base protects the stratum corneum while promoting hydration and elasticity.
The acidic pH (~4.2) helps suppress microbial growth and maintains compatibility with the natural acid mantle of the skin.
The dermal irritation test is only one part of the comprehensive safety package for Ion Gel ZCM-25®. Additional evaluations include:
All results were consistent and reproducible across models—animal, cellular, and human.
Based on the excellent outcome of the dermal irritation test, Ion Gel ZCM-25® is now suitable for clinical application in:
Its non-irritant and non-sensitizing profile makes it ideal for vulnerable skin and delicate healing phases.
The Primary Irritation Index (PII) is calculated using visual scoring for erythema and edema at multiple time points. A score of 0.0 is classified as:
This allows Ion Gel ZCM-25® to be labeled for safe use in wound beds, mucosal skin, and compromised tissue.
| Test Parameter | Outcome |
|---|---|
| Species | Rabbit (New Zealand) |
| Dose Applied | 0.5 mL |
| Human Equivalent | 5× standard dose |
| Application Area | 6.25 cm² |
| Erythema / Edema | 0 / 0 |
| Cumulative Reaction | None |
| PII Score | 0.0 |
| Final Classification | Non-Irritant (FEUM) |
The dermal irritation test provides essential validation for technologies like IBAL-based therapeutics. Unlike systemic drugs, topical solutions require direct compatibility with the skin’s immune interface.
This includes avoiding:
ION-ZCM1’s ionic structure avoids these problems by mimicking endogenous redox-active molecules already used by the body.
This validated dermal irritation test supports:
The strong safety data reduces risk for clinicians and enhances patient adherence during recovery.
The 2019 dermal irritation test conducted by UNIPREC confirms that Ion Gel ZCM-25® is completely non-irritating, even at five times the recommended dose. With a Primary Irritation Index of 0.0 and no dermal reactivity, the product sets a high benchmark for topical tolerability in medical devices.
Combined with cellular, human, and redox safety profiles, Ion Gel ZCM-25® continues to validate its reputation as a safe, effective, and innovative ion-based skin therapy.
Full protocol: Dermal Irritation – High Dose Rabbit Study
https://zcm25.com/resources
Explore related clinical safety and cytotoxicity studies
https://zcm25.com/resources